Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
Email Facebook Twitter Google+ LinkedIn Comments

Ophthalmic Tech Firm BioLight Reports 2015 IOPtiMate Revenue of $360K

Jun 2016
TEL AVIV, Israel — BioLight Life Sciences Ltd., a publically traded ophthalmic technology development firm, has reported its 2015 financial results and said it has achieved all previously announced 2015 milestones.

For the fiscal year ended Dec. 31, 2015, the company reported revenues of New Israeli Shekels (NIS) 1.4 million (about $360,000) from sales of its IOPtiMate System, a laser-based noninvasive surgical treatment for glaucoma.

Net loss for 2015 was approximately NIS 27.6 million ($7.1 million), or NIS 7.98 loss per share, compared to a net loss of approximately NIS 36 million ($9.2 million), or NIS 11.96 loss per share, for 2014. At the close of fiscal 2015, the company had approximately NIS 51 million ($13.1 million) in cash and short-term deposits.

The branch of medicine involved in the study of the anatomy, functions, diseases and treatments of the eye.

Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2018 Photonics Media, 100 West St., Pittsfield, MA, 01201 USA,
x Subscribe to BioPhotonics magazine - FREE!